Published in Arthritis Rheum on February 01, 2005
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum (2013) 3.55
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) (2010) 1.99
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis (2006) 1.59
Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol (2010) 1.35
Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol (2009) 1.27
Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol (2014) 1.23
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Clinical characteristics of patients with anti-Jo-1 antibodies: a single center experience. J Clin Rheumatol (2009) 1.17
B cells and immunological tolerance. J Invest Dermatol (2009) 1.15
Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des Devel Ther (2012) 1.12
Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. Curr Rheumatol Rev (2010) 1.07
Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders. Clin Exp Immunol (2009) 1.07
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord (2010) 0.98
Rituximab in the treatment of antisynthetase syndrome. Ann Rheum Dis (2006) 0.93
Idiopathic inflammatory myopathies. Semin Neurol (2012) 0.92
Update on rituximab. Ann Rheum Dis (2005) 0.91
Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies. Clin Med Insights Circ Respir Pulm Med (2015) 0.90
Rituximab in life threatening antisynthetase syndrome. Rheumatol Int (2009) 0.90
Cytokines in immune-mediated inflammatory myopathies: cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol (2014) 0.90
Immune mechanisms in the pathogenesis of idiopathic inflammatory myopathies. Arthritis Res Ther (2007) 0.90
Rituximab: a review of dermatological applications. J Clin Aesthet Dermatol (2009) 0.89
Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy. BMC Musculoskelet Disord (2010) 0.88
Spontaneous pneumomediastinum secondary to refractory dermatomyositis successfully treated with rituximab. Clin Rheumatol (2010) 0.84
The heterogeneity of juvenile myositis. Autoimmun Rev (2006) 0.83
Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab. Rheumatol Int (2011) 0.82
Idiopathic Inflammatory Myopathies: Clinical Approach and Management. Front Neurol (2016) 0.81
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol (2006) 0.81
Treatment of inflammatory myopathies. Postgrad Med J (2006) 0.81
In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice. PLoS One (2010) 0.81
Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr (2015) 0.81
Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials. Neurotherapeutics (2016) 0.80
Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy. Rheumatol Int (2009) 0.80
Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskelet Dis (2011) 0.79
Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol (2015) 0.78
Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial. Clin Exp Rheumatol (2014) 0.78
Idiopathic inflammatory myopathies. Neurol Clin (2014) 0.77
Idiopathic inflammatory myopathies: current and future therapeutic options. Neurotherapeutics (2008) 0.77
Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord (2008) 0.76
[Current treatments of dermatomyositis and polymyositis]. Z Rheumatol (2007) 0.76
Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. Clin Rev Allergy Immunol (2016) 0.76
Cutaneous Connective Tissue Diseases: Epidemiology, Diagnosis, and Treatment. Open Dermatol J (2009) 0.75
The use of biological therapy in refractory rheumatic diseases other than rheumatoid arthritis: experience at a tertiary care center in Lebanon. Rheumatol Int (2008) 0.75
Dermatomyositis masquerading as pulmonary embolism. Eur J Med Res (2009) 0.75
Current treatment strategies: collagen vascular diseases in children. Indian J Dermatol (2012) 0.75
Inflammatory myopathies: One-center experience. Eur J Rheumatol (2014) 0.75
Disease course and therapeutic approach in dermatomyositis: A four-center retrospective study of 100 patients. Neuromuscul Disord (2015) 0.75
Rituximab treatment in a case of antisynthetase syndrome with severe interstitial lung disease and acute respiratory failure. Multidiscip Respir Med (2011) 0.75
Evaluation and management of polymyositis. Indian J Dermatol (2012) 0.75
Targeted immunotherapy trials for idiopathic inflammatory myopathies. J Neurol (2012) 0.75
Cutaneous dermatomyositis in the era of biologicals. Semin Immunopathol (2015) 0.75
Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. Clinicoecon Outcomes Res (2017) 0.75
Cutaneous Manifestations of Dermatomyositis: a Comprehensive Review. Clin Rev Allergy Immunol (2017) 0.75